Summary & Overview
Abortion with D&C, Aspiration Curettage or Hysterotomy: Inpatient Reimbursement Overview
DRG 770 encompasses inpatient hospitalizations for abortion using dilation and curettage, aspiration curettage, or hysterotomy and defines the bundled payment for that episode of care. Understanding the clinical scope and coding implications is important because the Diagnosis-Related Group assignment drives Medicare prospective payment and influences hospital reimbursement for these procedures.
DRG 770 Overview
DRG 770 covers inpatient admissions for abortion procedures that include dilation and curettage, aspiration curettage, or hysterotomy performed for termination of pregnancy. This Diagnosis-Related Group captures resource use associated with procedure complexity, perioperative care, and any inpatient management of complications. It matters for Medicare payment because the DRG assignment determines the bundled prospective payment for the hospitalization. Accurate coding and documentation that reflect the procedure and clinical circumstances affect reimbursement and claims processing.
Clinical Trials
- Acute procedural optimization studies: randomized or observational trials evaluating techniques, anesthesia types, or peri-procedural protocols for first-trimester abortion procedures such as vacuum aspiration, manual vacuum aspiration, or surgical evacuation. These studies enroll patients presenting for elective or miscarriage-related abortion and compare outcomes like procedure completeness, immediate complications (bleeding, uterine perforation), analgesia needs, and operative time. Results inform clinicians on safest, most efficient procedural approaches and help payers anticipate resource use, procedure time, and short-term complication rates tied to reimbursement and length-of-stay.
- Comparative effectiveness and medication versus procedural care studies: trials comparing outcomes of medical abortion regimens (commonly used medications and dosing strategies) versus surgical options in varied patient groups, including gestational age subgroups and patients with comorbidities. These studies assess effectiveness, need for follow-up procedures, rates of incomplete abortion, patient-reported outcomes, and health-system utilization such as follow-up visits or readmissions. Findings are directly relevant to providers choosing care pathways and to payers and hospital administrators evaluating cost-effectiveness, avoidable re-procedures, and appropriate bundled payment models.
- Post-procedure recovery and longer-term outcomes research: prospective cohort studies and registries tracking patients after D&C or aspiration for outcomes such as infection rates, bleeding beyond discharge, reproductive sequelae, mental health impacts, and contraceptive uptake. These studies often focus on real-world follow-up, disparities in access to post-abortion care, and effectiveness of discharge counseling or follow-up modalities (telehealth versus in-person). Evidence from these studies helps health systems design post-discharge care pathways, reduces readmissions, and informs payer coverage decisions for follow-up services and preventive interventions.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.